Outlook Therapeutics LYTENAVA Wins FDA Approval for Wet AMD Treatment (OTLK)
What happened
Outlook Therapeutics announced FDA approval of LYTENAVA (bevacizumab-vikg) as an ophthalmic treatment for wet age-related macular degeneration, making it the only ophthalmic formulation of bevacizumab to date to secure an FDA green light in this indication. The approval marks a regulatory milestone for Outlook, which had pursued this designation after years of clinical development. The company's release cited the unmet need in the wet AMD patient population and positioned LYTENAVA as a distinct, purpose-formulated option from compounded bevacizumab alternatives.
The QL Read
No QuantLogix signal data is available for OTLK in today's feed. What to watch: initial reimbursement coverage decisions and any competing label expansions from established anti-VEGF players — those are the near-term catalysts likely to shape commercial traction.